12 October 2023 in Journal of Internal Medicine
Background: Chronic kidney disease (CKD) is an age‐related disease that displays multiple features of accelerated ageing. It is currently unclear whether the two treatment options for end‐stage kidney disease (dialysis and kidney transplantation [KT]) ameliorate the accelerated uremic ageing process.Methods: Data on clinical variables and blood DNA methylation (DNAm) from CKD stage G3–G5 patients were used to estimate biological age based on blood biomarkers (phenotypic age [PA], n = 333), skin autofluorescence (SAF age, n = 199) and DNAm (Horvath, Hannum and PhenoAge clocks, n = 47). In the DNAm cohort, we also measured the change in biological age 1 year after the KT or initiation of dialysis. Healthy subjects recruited from the general population were included as controls.Results: All three DNAm clocks indicated an increased biological age in CKD G5. However, PA and SAF age tended to produce implausibly large estimates of biological age in CKD G5. By contrast, DNAm age was 4.9 years (p = 0.005) higher in the transplantation group and 5.9 years (p = 0.001) higher in the dialysis group compared to controls. This age acceleration was significantly reduced 1 year after KT, but not after 1 year of dialysis.Conclusions: Kidney failure patients displayed an increased biological age as estimated by DNAm clocks compared to population‐based controls. Our results suggest that KT, but not dialysis, partially reduces the age acceleration.
11 February 2022 in Journal of Internal Medicine
Background: Progression of vascular calcification causes cardiovascular disease, which is the most common cause of death in chronic kidney failure and after kidney transplantation (KT). The prognostic impact of the extent of medial vascular calcification at KT is unknown.Methods: In this prospective cohort study, we investigated the impact of medial calcification compared to a mix of intimal and medial calcification represented by coronary artery calcification (CAC score) and aortic valve calcification in 342 patients starting on kidney failure replacement therapy. The primary outcomes were cardiovascular events (CVE) and death. The median follow‐up time was 6.4 years (interquartile range 3.7–9.6 years). Exposure was CAC score and arteria epigastrica medial calcification scored as none, mild, moderate, or severe by a pathologist at time of KT (n = 200). We divided the patients according to kidney failure replacement therapy during follow‐up, that is, living donor KT, deceased donor KT, or dialysis.Results: Moderate to severe medial calcification in the arteria epigastrica was associated with higher mortality (p = 0.001), and the hazard ratio for CVE was 3.1 (95% confidence interval [CI] 1.12–9.02, p < 0.05) compared to no or mild medial calcification. The hazard ratio for 10‐year mortality in the dialysis group was 33.6 (95% CI, 10.0–113.0, p < 0.001) compared to living donor recipients, independent of Framingham risk score and prevalent CAC.Conclusion: Scoring of medial calcification in the arteria epigastrica identified living donor recipients as having 3.1 times higher risk of CVE, independent of traditional risk factors. The medial calcification score could be a reliable method to identify patients with high and low risk of CVE and mortality following KT.
4 August 2021 in Transplant International
Background Kidney transplantation (Ktx) in elderly has become increasingly accepted worldwide despite their higher burden of comorbidities. We investigated important risk factors affecting long-term patient and graft survival. Methods We included all (n=747) Ktx patients >60 years from 2000 to 2012 in Sweden. Patients were age-stratified; 60-64, 65-69 and >70 years. Follow-up time was up to 10 years (median 7.9 years, 75% percentile >10 years). Primary outcome was 10-year patient survival in age-stratified groups. Secondary outcomes were 5- year patient and graft-survival in age-stratified groups and the impact of risk factors including Charlson comorbidity index on patient and graft-survival. Results Mortality was higher in patients >70 years, after 10 years (HR 1.94; 95% CI 1.24-3.04; p=0.004). Males had a higher 10-year risk of death (HR 1.39; CI 95% 1.04-1.86; p=0.024). Five-year patient survival did not differ between age-groups. In multivariate Cox analysis (n=500) hazard ratio for 10-year mortality was 4.6 in patients with Charlson comorbidity index ≥7 vs <4 (95% CI 2.42-8.62; p=0.0001) Conclusion Higher Charlson comorbidity index identified ESKD patients with 4.6 times higher risk of death after Ktx. We suggest that this index should be used as a part of the pre-operative evaluation in elderly.
9 February 2026 in Nephrology Dialysis Transplantation
Thromboembolic and atherosclerotic disorders, necessitating antithrombotic therapies, are prevalent among patients with advanced chronic kidney disease (CKD), as well as in kidney transplant (KT) recipients. However, the optimal management of antithrombotic therapies in these patients remains uncertain due to conflicting evidence and the exclusion of advanced CKD and KT recipients from major randomized controlled trials. Additionally, the perioperative management of antithrombotic therapy in end-stage kidney disease patients undergoing transplantation requires specific attention. This clinical practice document prepared by experts from the DESCaRTES Working Group of the European Renal Association (ERA) and European Kidney Transplant Association (EKITA) from European Society of Organ Transplantation (ESOT) following European Renal Best Practice (ERBP) guidelines is designed to support clinicians in decision making on antithrombotic therapies in KT candidates and recipients. Following a detailed systematic literature review, it presents current knowledge in epidemiology and pathophysiology and summarizes all relevant studies in this topic.
26 February 2026 in Clinical Kidney Journal
Background: Frailty has been identified as an important determinant of adverse transplant-related outcomes; however, its integration into routine kidney transplant practice remains limited. Methods: A web-based cross-sectional survey assessing current practice patterns and perceptions on frailty assessments among transplant physicians distributed by The DESCaRTES working group of the European Renal Association. The survey consisted of questions about frailty perceptions and practices both pre- and post-transplant. Results: A total of 134 responses (response rate 39.2%) were recorded. Although 98.5% recognized frailty as a risk factor for adverse outcomes, only 6.7% reported routinely performing a standardized frailty assessment in pre-transplant evaluations. Nearly 30% never evaluated frailty, and 24.6% did so only in selected high-risk patients, primarily based on age, comorbidities, or prolonged dialysis duration. Physical function was recognized as the most important component of frailty assessments; however, no single assessment tool was consistently implemented. The main barriers to integrating frailty assessments into clinical practice were lack of trained staff, absence of standardized guidelines, and uncertainty about clinical usefulness. Post-transplant frailty assessments were rarely conducted routinely, despite 74.6% acknowledging their potential value. Conclusions: Despite widespread recognition of frailty as a significant determinant influencing transplant outcomes, its routine assessment in clinical practice remains limited across European centers. Variability in assessment tools, lack of guidelines, and insufficient training resources contribute to this gap. Addressing these barriers through targeted education, validation of practical assessment tools, and consensus-driven protocols is essential to support the integration of frailty evaluation into both pre- and post-transplant care.